The concentration or appearance rate of cancer antigen 125 (CA125) in peritoneal dialysis (PD) effluent has been used for many years as a biomarker for mesothelial cell mass in patients on PD. However, this marker has limitations, and emerging evidence has raised doubts as to its significance. This review explores our current understanding of CA125, its prominent role in studies of “biocompatible” PD solutions, and the ongoing uncertainty concerning its interpretation as a measure of mesothelial cell health.
DaviesS.J., PhillipsL., GriffithsA.M., RussellL.H., NaishP.F., RussellG.I.What really happens to people on long term peritoneal dialysis?Kidney Int1998; 54: 2207–17.
2.
BastR.C.Jr., XuF.J., YuY.H., BarnhillS., ZhangZ., MillsG.B.CA 125: the past and the future.Int J Biol Markers1998; 13: 179–87.
3.
ZeimetA.G., MarthC., OffnerF.A., ObristP., Uhl-SteidlM., FeichtingerH.Human peritoneal mesothelial cells are more potent than ovarian cancer cells in producing tumor marker CA-125.Gynecol Oncol1996; 62: 384–9.
4.
VisserC.E., Brouwer-SteenbergenJ.J., BetjesM.G., KoomenG.C., BeelenR.H., KredietR.T.Cancer antigen 125: a bulk marker for the mesothelial mass in stable peritoneal dialysis patients.Nephrol Dial Transplant1995; 10: 64–9.
5.
KredietR.T.Dialysate cancer antigen 125 concentration as marker of peritoneal membrane status in patients treated with chronic peritoneal dialysis.Perit Dial Int2001; 21: 560–7.
6.
Ho-dac-PannekeetM.M., HiralallJ.K., StruijkD.G., KredietR.T.Longitudinal follow-up of CA-125 in peritoneal effluent.Kidney Int1997; 51: 888–93.
7.
WilliamsJ.D., TopleyN., CraigK.J., MackenzieR.K., PischetsriederM., LageC.The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (Balance) on the peritoneal membrane.Kidney Int2004; 66: 408–18.
RippeB., SimonsenO., HeimbürgerO., ChristenssonA., HaraldssonB., StelinG.Long term clinical effects of a peritoneal dialysis fluid with less glucose degradation products.Kidney Int2001; 59: 348–57.
10.
SzetoC.C., ChowK.M., LamC.W., LeungC.B., KwanB.C., ChungK.Y.Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products—a 1-year randomized control trial.Nephrol Dial Transplant2007; 22: 552–9.
11.
ChoiH.Y., KimD.K., LeeT.H., MoonSJ, HanS.H., LeeJ.E.The clinical usefulness of peritoneal dialysis fluids with neutral pH and low glucose degradation product concentration: an open randomized prospective trial.Perit Dial Int2008; 28: 174–82.
12.
Haag-WeberM., KrämerR., HaakeR., IslamM.S., PrischlF., HaugU.Low-GDP fluid (Gambrosol Trio) attenuates decline of residual renal function in PD patients: a prospective randomized study.Nephrol Dial Transplant2010; 25: 2288–96.
13.
FusshöllerA., PlailM., GrabenseeB., PlumJ.Biocompatibility pattern of a bicarbonate/lactate-buffered peritoneal dialysis fluid in APD: a prospective, randomized study.Nephrol Dial Transplant2004; 19: 2101–6.
14.
LaiK.N., LaiK.B., SzetoC.C., HoK.K., PoonP., LamC.W.Dialysate cell population and cancer antigen 125 in stable continuous ambulatory peritoneal dialysis patients: their relationship with transport parameters.Am J Kidney Dis1997; 29: 699–705.
15.
BreborowiczA., BreborowiczM., PydaM., PołubinskaA., OreopoulosD.Limitations of CA125 as an index of peritoneal mesothelial cell mass.Nephron Clin Pract2005; 100: c46–51.
16.
PannekeetM.M., ZemelD., KoomenG.C., StruijkD.G., KredietR.T.Dialysate markers of peritoneal tissue during peritonitis and in stable CAPD.Perit Dial Int1995; 15: 217–25.
17.
TopleyN., MichaelD., BowenT.CA125: holy grail or a poisoned chalice.Nephron Clin Pract2005; 100: c52–4.
18.
TopleyN.Membrane longevity in peritoneal dialysis: impact of infection and bio-incompatible solutions.Adv Ren Replace Ther1998; 5: 179–84.
19.
DelarueJ., MaingourdC.Acute metabolic effects of dialysis fluids during CAPD.Am J Kidney Dis2001; 37(Suppl 2): S103–7.
MontenegroJ., SarachoR.M., MartínezI.M., MuñozR.I., OcharanJ.J., ValladaresE.Long term clinical experience with pure bicarbonate peritoneal dialysis solutions.Perit Dial Int2006; 26: 89–94.
22.
FangW., MullanR., ShahH., MujaisS., BargmanJ.M., OreopoulosD.G.Comparison between bicarbonate/ lactate and standard lactate dialysis solution in peritoneal transport and ultrafiltration: a prospective, crossover single-dwell study.Perit Dial Int2008; 28: 35–43.
23.
KimS., OhJ., KimS., ChungW., AhnC., KimS.G.Benefits of biocompatible PD fluid for preservation of residual renal function in incident CAPD patients: a 1 year study.Nephrol Dial Transplant2009; 24: 2899–908.
24.
MartikainenT.A., TeppoA.M., Grönhagen-RiskaC., EkstrandA.V.Glucose-free dialysis solutions: inductors of inflammation or preservers of peritoneal membrane?Perit Dial Int2005; 25: 453–60.
